Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update

Detailed price information for Allogene Therapeutics Inc (ALLO-Q) from The Globe and Mail including charting and trades.
Le Lézard

Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary ...

Vertex Pharmaceuticals Incorporated today announced updated data for povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) from the ongoing RUBY-3 trial at the ...